Literature DB >> 17393117

Expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of bladder.

Xing Ai1, Xu Zhang, Zhun Wu, Xin Ma, Zhenghua Ju, Baojun Wang, Taoping Shi.   

Abstract

The expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of bladder (TCCB) and its clinical significance were investigated. Immunohistochemistry was used to detect KAI1/CD82 and MRP-1/CD9 protein expression in 52 TCCB specimens. Correlation between the expression of KAI1/CD82 and MRP-1/CD9 to clinicopathologic factors was statistically analyzed. The results showed that the positive rate of KAI1/CD82 and MRP-1/CD9 in TCCB was 50% and 61.5%, respectively. The MRP-1/CD9 and KAI1/CD82 expression was significantly associated with grade of TCCB (P<0.05), but no correlation was found between MRP-1/CD9 or KAI1/CD82 expression and clinical stage of TCCB (P>0.05). The expression level of MRP-1/CD9 and KAI1/CD82 in recurrent TCCB samples was lower than that in non-recurrent samples (P<0.05). Meanwhile, the correlation between the KAI1/CD82 expression and MRP-1/CD9 expression was statistically significant (r=0.316, P<0.05). It was concluded that KAI1/CD82 and MRP-1/CD9 expression may be important prognostic indicators and potentially useful for assessing the biological behavior of TCCB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393117     DOI: 10.1007/s11596-007-0123-0

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

1.  KAI1 protein is down-regulated during the progression of human breast cancer.

Authors:  X Yang; L Wei; C Tang; R Slack; E Montgomery; M Lippman
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

2.  Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression.

Authors:  M Adachi; T Taki; T Konishi; C I Huang; M Higashiyama; M Miyake
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

3.  New clue to prostate cancer spread.

Authors:  J Marx
Journal:  Science       Date:  1995-05-12       Impact factor: 47.728

4.  Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation.

Authors:  M Ono; K Handa; D A Withers; S Hakomori
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

5.  Inverse correlation between KAI1 mRNA levels and invasive behaviour in bladder cancer cell lines.

Authors:  P Jackson; E A Kingsley; P J Russell
Journal:  Cancer Lett       Date:  2000-08-01       Impact factor: 8.679

6.  KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.

Authors:  J T Dong; P W Lamb; C W Rinker-Schaeffer; J Vukanovic; T Ichikawa; J T Isaacs; J C Barrett
Journal:  Science       Date:  1995-05-12       Impact factor: 47.728

7.  Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer.

Authors:  M Miyake; K Nakano; S I Itoi; T Koh; T Taki
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

8.  Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases.

Authors:  H Friess; X Z Guo; P Berberat; H U Graber; A Zimmermann; M Korc; M W Büchler
Journal:  Int J Cancer       Date:  1998-08-21       Impact factor: 7.396

9.  Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.

Authors:  Paulette Mhawech; Françoís Herrmann; Monique Coassin; Louis Guillou; Christophe E Iselin
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

10.  Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility.

Authors:  M Miyake; M Koyama; M Seno; S Ikeyama
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

  10 in total
  1 in total

1.  Expressions of KAI1 and E-cadherin in nonsmall cell lung cancer and their correlation with vasculogenic mimicry.

Authors:  Hongfei Ci; Zhouyi Xu; Jing Xu; Yichao Wang; Shiwu Wu
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.